IASO208 Cleared for U.S. In Vivo CAR-T Testing
FDA cleared IASO208, a CD20-directed in vivo CAR-T candidate built on a replication-incompetent, self-inactivating third-generation lentiviral vector, for U.S. clinical testing in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. IASO Bio expects to…
